Minimization of ragweed allergy immunotherapy costs through use of the sublingual immunotherapy tablet in Canadian children with allergic rhinoconjunctivitis

[1]  M. Tankersley,et al.  Preference for Immunotherapy with Tablets by People with Allergic Rhinitis , 2021, Patient preference and adherence.

[2]  A. Ellis,et al.  Sublingual immunotherapy tablet: a cost-minimizing alternative in the treatment of tree pollen-induced seasonal allergic rhinitis in Canada , 2021, Allergy, Asthma & Clinical Immunology.

[3]  G. Ciprandi,et al.  Under-prescription of allergen-immunotherapy: why is it important to prescribe it in childhood instead? , 2021, Immunotherapy.

[4]  D. Bernstein,et al.  Efficacy and Safety of Ragweed SLIT-Tablet in Children with Allergic Rhinoconjunctivitis in a Randomized, Placebo-Controlled Trial. , 2020, The journal of allergy and clinical immunology. In practice.

[5]  A. Ellis,et al.  Patient and physician perceptions of seasonal allergic rhinitis and allergen immunotherapy: a parallel physician patient survey , 2020, Allergy, Asthma & Clinical Immunology.

[6]  L. Cox,et al.  The Cost-Effectiveness of Allergen Immunotherapy Compared with Pharmacotherapy for Treatment of Allergic Rhinitis and Asthma. , 2020, Immunology and allergy clinics of North America.

[7]  A. Ellis,et al.  Sublingual immunotherapy tablet for the treatment of house dust mite allergic rhinitis in Canada: an alternative to minimize treatment costs? , 2019, Allergy, Asthma & Clinical Immunology.

[8]  D. Price,et al.  Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. , 2019, The Journal of allergy and clinical immunology.

[9]  Y. Okamoto,et al.  Safety profile and immunological response of dual sublingual immunotherapy with house dust mite tablet and Japanese cedar pollen tablet. , 2019, Allergology international : official journal of the Japanese Society of Allergology.

[10]  S. Henderson,et al.  Aeroallergens in Canada: Distribution, Public Health Impacts, and Opportunities for Prevention , 2018, International journal of environmental research and public health.

[11]  J. Allam,et al.  Comparison of allergy immunotherapy medication persistence with a sublingual immunotherapy tablet versus subcutaneous immunotherapy in Germany. , 2018, The Journal of allergy and clinical immunology.

[12]  A. Sheikh,et al.  EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis , 2018, Allergy.

[13]  A. Sheikh,et al.  Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta‐analysis , 2017, Allergy.

[14]  Simon S. Bensnes.  You sneeze, you lose:: The impact of pollen exposure on cognitive performance during high-stakes high school exams. , 2016, Journal of health economics.

[15]  K. Damm,et al.  Patient preferences in allergy immunotherapy (AIT) in Germany – a discrete-choice-experiment , 2016, Health Economics Review.

[16]  M. San Miguel Moncín,et al.  Comprehensive Study of Patients’ Compliance with Sublingual Immunotherapy in House Dust Mite Perennial Allergic Rhinitis , 2016, Advances in Therapy.

[17]  Jennifer G Chester,et al.  Patient preferences for route of allergy immunotherapy: a comparison of four delivery methods , 2016, International forum of allergy & rhinology.

[18]  D. Bernstein,et al.  Sequential Treatment Initiation with Timothy Grass and Ragweed Sublingual Immunotherapy Tablets Followed by Simultaneous Treatment Is Well Tolerated. , 2016, The journal of allergy and clinical immunology. In practice.

[19]  R. Lockey,et al.  Administration and Burden of Subcutaneous Immunotherapy for Allergic Rhinitis in U.S. and Canadian Clinical Practice , 2015, Journal of managed care & specialty pharmacy.

[20]  J. Bousquet,et al.  Sublingual immunotherapy: World Allergy Organization position paper 2013 update , 2014, The World Allergy Organization journal.

[21]  T. Casale,et al.  Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. , 2013, The Journal of allergy and clinical immunology.

[22]  D. Menzies,et al.  Validation des codes de diagnostic de la CIM-9 pour la dysplasie bronchopulmonaire dans les bases de données de la Régie de l'assurance-maladie du Québec , 2012 .

[23]  W. Reisacher,et al.  A comparison of attrition rates in patients undergoing sublingual immunotherapy vs subcutaneous immunotherapy , 2012, International forum of allergy & rhinology.

[24]  P. Keith,et al.  The burden of allergic rhinitis (AR) in Canada: perspectives of physicians and patients , 2012, Allergy, Asthma & Clinical Immunology.

[25]  S. Spector,et al.  Allergen immunotherapy: a practice parameter third update. , 2007, The Journal of allergy and clinical immunology.

[26]  A. Buist,et al.  Geographical variations in the prevalence of atopic sensitization in six study sites across Canada , 2010, Allergy.

[27]  Ketan K. Sheth,et al.  Burden of allergic rhinitis: results from the Pediatric Allergies in America survey. , 2009, The Journal of allergy and clinical immunology.

[28]  Pat Finerty,et al.  Ontario Ministry of Health and Long-term Care forecast for hip replacements. , 2009, Healthcare quarterly.

[29]  A. Sheikh,et al.  Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. , 2007, The Journal of allergy and clinical immunology.

[30]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[31]  J. Hébert,et al.  Comparison of alum-precipitated aqueous extracts and modified ragweed tyrosine adsorbate vaccine in the treatment of ragweed hay fever. , 1988, Annals of allergy.

[32]  R. Dawson,et al.  The Government of Canada , 1948 .

[33]  Guidelines for the Economic Evaluation of Health Technologies in Ireland 2014 , 2022 .